cross-posted from: https://lemmy.world/post/9298788

The Biden Administration on Thursday announced it is setting new policy that will allow it to seize patents for medicines developed with government funding if it believes their prices are too high.

The policy creates a roadmap for the government’s so-called march-in rights, which have never been used before. They would allow the government to grant additional licenses to third parties for products developed using federal funds if the original patent holder does not make them available to the public on reasonable terms.

Under the draft roadmap, seen by Reuters, the government will consider factors including whether only a narrow set of patients can afford the drug, and whether drugmakers are exploiting a health or safety issue by hiking prices.

“We’ll make it clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House adviser Lael Brainard said on a press call.

  • mommykink
    link
    fedilink
    2311 months ago

    What a good piece of legislation can really make a difference for so many Americans. I’m excited to see this never be used and quietly get taken off the books in three years by Republicans.

  • the_post_of_tom_joad [any, any]
    link
    fedilink
    English
    14
    edit-2
    11 months ago

    Maaan i wish there was some more info on what the white house ‘believes’ is expensive, cuz whether this policy could be amazing or useless depends entirely upon that question mark

    • @BossDj@lemm.ee
      link
      fedilink
      511 months ago

      Leaving it vague allows the government more leeway, and companies less opportunities for “well, technically” gotchas from their scores of lawyers

      • the_post_of_tom_joad [any, any]
        link
        fedilink
        English
        511 months ago

        Surely youre right, because the answer of whether they are too high is ‘yes’ for every drug sold in the us.

        I guess I’m interested in how they are using it, if at all. If Biden plans on reducing 'scrips in time for the election it could help pump his numbers up i guess? I’m just spitballing, cuz i can’t see how it’s gonna be used. i am too cynical after all these years to believe the poor get any breaks.

        • @BossDj@lemm.ee
          link
          fedilink
          411 months ago

          Of you want to be cynical, I’ll bet it’s only used on companies with whom the administration makes behind the scenes deals with before going public with it. Financial or helping them look good, or offering future contracts

    • @captainlezbian@lemmy.world
      link
      fedilink
      1211 months ago

      That’s a huge portion of them. Taxpayers help out a lot at early levels of drug discovery with things like public universities and research grants.

    • @God_Is_Love@reddthat.com
      link
      fedilink
      311 months ago

      Man that’s a really important piece of information, it should be in the article title. The greediest companies are not the tax payer funded ones

      • @JillyB@beehaw.org
        link
        fedilink
        311 months ago

        A good analysis would be to determine what portion of the drug market would fall in this category. I imagine the amount of drug R&D done with some amount of federal dollars is pretty high.

        If this policy has enough teeth to scare pharma corps, then it will probably change their behaviors. They could decide that they need to use minimal federal funding which could slow drug development. I wonder if this policy (or others) is meant to address this potential.

      • @Not_mikey@lemmy.world
        link
        fedilink
        211 months ago

        No, the greediest companies take all the tax payer funding and research they can before patenting it and pretending they made it, see moderna. Why pay for your research when you can get the taxpayers to do it?